Delivery Order SPE2DB24D1201-SPE2DB25FJDYD
- Not listed
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order by the Defense Logistics Agency for $19,042.85 to supply Dupixent 300 mg/2 mL syringes. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 6, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order by the Defense Logistics Agency for the supply of Dupixent 300 mg/2 ml syringes (2 ml). The contract is valued at $3,960.88 with a firm fixed price and an ultimate completion date of July 31, 2025. This award represents a competitive, non-set-aside procurement and is classified as a child contract, indicating it derives from a larger contract vehicle. The Defense Logistics Agency,...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $86,474.81 for Dupixent 300mg/2mL (2 units) under a firm fixed price contract with the Defense Logistics Agency Medical Supply Chain. The award was made on August 22, 2025, with an ultimate completion date of September 19, 2025. This non-set-aside, competitively awarded delivery order will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, PA, was awarded a delivery order by the Defense Logistics Agency on August 4, 2025, for Dupixent 200 mg/1.14 mL syringes valued at $8,195.94. This firm fixed-price contract, with an ultimate completion date of August 5, 2025, carries no set-aside designation and represents a competitively awarded procurement. The delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 21, 2025, for the supply of Dupixent 300 mg/2 ml syringes. The contract is valued at $22,619.31 and represents a firm fixed-price delivery order with an ultimate completion date of July 22, 2025. The performance location is the company's corporate office in Conshohocken, Pennsylvania. This is a non-set-aside award, indicating it was competitively awarded. The delivery order is issued under...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $4,735.23 by the Defense Logistics Agency on August 8, 2025, for the supply of Dupixent 300 mg/2 mL syringes. The contract is firm fixed price with no set-aside designation, indicating competitive award, and is scheduled for completion by August 11, 2025. Performance will take place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Dupixent 300 mg/2 ml syringes. The contract is a firm-fixed-price delivery order with a ceiling value of $16,414.50 and a completion date of September 10, 2024. AmerisourceBergen, through its Corporate Office division, has been awarded this contract to provide the medication to support military treatment facilities and other federal...
- The Defense Logistics Agency awarded a delivery order valued at $17,017.67 to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's headquarters location...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $10,302.48 on July 25, 2025, for the supply of Dupixent 300 mg/2 ml syringes. The contract is competitively awarded with no set-aside designation and carries an ultimate completion date of July 28, 2025. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $26,119.30 for Dupixent 300 mg/2 ml pen (2 ml) under a firm fixed price contract with the Defense Logistics Agency's Medical Supply Chain. The award was made on July 30, 2025, with an ultimate completion date of July 31, 2025, and represents a non-set-aside, competitively awarded contract. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- SPE2DB24D1201Indefinite Delivery Contract
- SPE2DB24D1201-SPE2DB25FJDYDDelivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order by the Defense Logistics Agency for the supply of Dupixent 300 mg/2 ml syringes (2 ml configuration) valued at $5,768.54. The contract is a firm fixed price delivery order awarded on August 18, 2025, with an ultimate completion date of August 19, 2025, and carries no set-aside designation. This award represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999 and extends through December 2026. This delivery order falls within AmerisourceBergen's extensive portfolio of pharmaceutical supply contracts supporting the Defense Health Agency and other federal healthcare systems. The company serves as a critical vendor for military medical procurement through its prime IDC with DLA, which enables the delivery of a comprehensive range of brand-name and generic pharmaceuticals, specialty medications, and medical supplies across multiple therapeutic domains. The Dupixent product supplied under this award is a biologic medication used to treat certain allergic and inflammatory conditions, reflecting the company's role in supporting specialized pharmaceutical needs within the federal healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.8k | 8/18/25 |